Engineered immune cells take aim at tough leukemia
NCT ID NCT04219163
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-phase trial tests a new type of cell therapy for adults with acute myeloid leukemia (AML) that has returned or not responded to standard treatment. The therapy uses the patient's own T cells, which are modified in the lab to recognize and attack leukemia cells carrying a protein called CLL-1. The study aims to find a safe dose and see if the cells can shrink the cancer, with the ultimate goal of getting patients well enough for a stem cell transplant.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CLL-1 CAR T-cells (a type of immune cell therapy)
- What this could lead to
- If successful, this could lead to a new treatment option for patients with hard-to-treat acute myeloid leukemia, potentially helping them achieve remission before a stem cell transplant.
- What could go wrong
- This is a very early Phase 1 trial with only 18 participants, so it is too small to prove effectiveness. The therapy may cause severe side effects, and it is not yet known if the cells will last long enough to control the cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Texas Children's Hospital
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Could muscle loss predict blood cancer outcomes?
- Can a modified enzyme starve Hard-to-Treat blood cancers?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?